Post-Surgery Recovery & Scar Minimization Guide

Part 1

The Biology of Wound Healing & Scarring

The Four Phases of Wound Healing

1. Hemostasis

Minutes to Hours

Platelet aggregation and fibrin clot formation. The clot serves as a scaffold for incoming repair cells.

2. Inflammation

Days 1–5

Neutrophils and macrophages clear debris and bacteria. Pro-inflammatory cytokines (TNF-α, IL-1, IL-6) recruit repair cells. This phase is essential — aggressively suppressing early inflammation impairs healing.

3. Proliferation

Days 3–21

Fibroblasts produce collagen and extracellular matrix (ECM). Angiogenesis supplies the wound with new blood vessels. Keratinocytes re-epithelialize the surface.

4. Remodeling

Weeks to 2+ Years

Type III collagen is gradually replaced by Type I. The scar matures, softens, and flattens. This phase determines final scar quality and lasts up to 2 years — interventions remain beneficial for months.

Why Scars Form Instead of Regeneration

Fetuses heal without scars. Why can't adults? Key differences:

TGF-β ratio: Fetal tissue has high TGF-β3 (anti-fibrotic) and low TGF-β1 (pro-fibrotic). Adult wounds have the opposite. Shifting this ratio is a key therapeutic target.
Fibroblast populations: Fetal wounds are dominated by Engrailed-1 negative fibroblasts (ENFs) that promote regeneration. Adult wounds activate Engrailed-1 positive fibroblasts (EPFs) that produce scar.
Inflammation: Fetal wounds have attenuated inflammatory responses. The adaptive immune system actively promotes scarring.
Mechanical tension: Larger organisms experience greater forces on wounds. Tension activates the mechanotransduction cascade that drives fibrosis.
ECM composition: Fetal ECM is hyaluronic acid-rich, supporting regenerative healing.
Evolutionary trade-off: Scarring is faster and cheaper than regeneration — it prevents infection at the cost of tissue quality.

The Mechanotransduction Cascade

This is the most important framework from recent research. Every step is a potential intervention point:

Mechanical Tension on Wound

↓

Piezo1 channels + Integrins sense tension

Block: GsMTx4

↓

FAK (Focal Adhesion Kinase) activation

Block: PF-573228

↓

Calcium signaling

↓

YAP nuclear translocation

Block: Verteporfin

↓

Engrailed-1 transcription activated

↓

ENF fibroblasts → EPF fibroblasts (scar-forming)

↓

FIBROSIS / SCARRING

Reducing tension (Botox, embrace devices, silicone sheets) or blocking YAP (verteporfin) can interrupt this cascade.

Part 2

Supplements & Nutraceuticals

Tier 1: Strong Evidence Recommended

Vitamin C Essential Confidence: Medium-High

Dose 500–1000 mg/day (split)

Timing Start 2+ weeks pre-surgery

Required cofactor for collagen synthesis (proline & lysine hydroxylation). Involved in ALL healing phases. Deficiency = scurvy = failed wound healing. Especially critical for vocal fold repair.

Zinc Confidence: Medium

Dose 15–30 mg/day (picolinate or bisglycinate)

Timing Start 2 weeks pre-surgery

Cofactor for 300+ enzymes. Essential for cell division, protein synthesis, immune function. Deficiency is common and significantly impairs healing. >40 mg/day long-term can deplete copper.

Collagen Peptides Confidence: Medium

Dose 10–20 g/day hydrolyzed

Timing Pre-surgery through recovery

Acts as signaling molecules (Pro-Hyp dipeptides stimulate fibroblast activity) rather than direct structural building blocks. One small RCT (N=31 burn patients receiving a multi-component supplement) showed 3.7x wound healing hazard ratio (95% CI 1.4–9.5). Validated tier: Tier 2 (downgraded from Tier 1 due to limited and industry-funded evidence).

Arginine + Glutamine Confidence: Medium (infection) Low (scarring)

Immunonutrition

Dose Arg 4.5–9 g/day, Gln 10–30 g/day

Conditionally essential during surgical stress. Arginine is a nitric oxide precursor supporting wound blood flow. Glutamine supports immune cells and gut barrier. Meta-analyses measure infectious complications, NOT wound healing quality; benefits largely limited to malnourished patients. ESPEN gives standalone arginine Grade 0. Validated tier: Tier 2 (infection prevention) / Insufficient (scarring). Safety note: Arginine is contraindicated in sepsis (increased mortality) and may reactivate herpes simplex. High-dose glutamine in multi-organ failure increases mortality (REDOX trial, NEJM 2013).

Saccharomyces boulardii Gut Health High (AAD) Low (wound healing)

Dose 250–500 mg twice daily

Timing Start before surgery; take first

Uniquely survives antibiotics (unlike bacterial probiotics). 80% of trials showed efficacy preventing antibiotic-associated diarrhea. Gut microbiome disruption from surgical antibiotics lasts 6–8 weeks.

Topical Silicone Confidence: Medium

Sheets or gel (for external wounds)

Timing Once wound is fully closed

Duration 12–24 hrs/day for 3–6 months

Internationally recommended first-line scar prevention. However, Cochrane reviews rate ALL evidence LOW or VERY LOW certainty by GRADE criteria; a 2025 RCT found no difference vs. petrolatum. Guideline recommendations do not equal strong RCT evidence. Validated tier: Tier 2 (downgraded from Tier 1). For VFSRAC, the surgical site is internal, so this applies only to any external incisions.

Tier 2: Moderate Evidence Reasonable Additions

Curcumin Stop 2wk pre-surgery Confidence: Low-Medium

Dose 500–1000 mg/day with piperine

Timing STOP 2 weeks before surgery. Resume day 3–5 post-op.

Anti-inflammatory, antioxidant. Prevents hypertrophic scarring in preclinical models. Reduces TGF-β-driven fibrosis. Bleeding risk via platelet inhibition — must stop before surgery.

Vitamin D3 + K2 Medium (D3) Very Low (K2)

Dose D3: 2000–5000 IU, K2 (MK-7): 100–200 mcg

Timing Pre-surgery, continue throughout

D3 reduces keloid fibroblast proliferation and has immune-supportive evidence. K2 “tissue repair” claim has zero human wound healing evidence; extrapolated from bone biology. Safety note: K2 is contraindicated with warfarin/anticoagulants (common post-surgery).

NAC (N-Acetyl Cysteine) Confidence: Low-Medium

Dose 600–1200 mg/day

Precursor to glutathione (master antioxidant). Animal scar studies used intradermal injection, not oral; single research group; oral bioavailability <10%. Liver protection from anesthesia metabolites. Mucolytic properties. Validated tier: Tier 2 (liver/pulmonary) / Tier 3 (scar reduction). Safety note: Anticoagulant interaction (decreased platelet aggregation); nitroglycerin interaction; GI intolerance in 23% of patients.

Bromelain Confidence: Medium

Dose 500–1000 mg/day, empty stomach

Timing Start 3 days before surgery

Pineapple enzyme. RCTs confirm reduced pain/swelling post-surgery (primarily dental surgery data). Vocal cord study (EVAN) was observational combo product, not bromelain-specific. Safety note: Fibrinolytic mechanism directly contradicts pre-surgical use recommendation (bleeding risk paradox).

Quercetin VF-Specific Data Confidence: Low-Medium

Dose 500–1000 mg/day (with bromelain)

Timing Post-surgery, ~day 5+

Demonstrated antifibrotic effects specifically on vocal fold fibroblasts in one unreplicated animal study. Acts via TGF-β1/Smad signaling (not AKT/mTOR, which was from a different tracheal stenosis study). Animal model: reduced VF scarring, lower fibroblast density, improved collagen organization. The only supporting human RCT was for cesarean section wounds, not vocal folds. Validated tier: Tier 3 (downgraded from Tier 2).

Centella Asiatica (Gotu Kola) Medium (topical) Low (oral)

Dose 500–1000 mg standardized extract

Most clinical scar evidence is for topical application, not oral. Oral evidence limited to two non-randomized registry studies. Blocks TGF-β/Smad pathway. Contains triterpenoids (asiaticoside, madecassoside) that modulate collagen synthesis. Safety note: Rare hepatotoxicity risk (4 published cases).

Tier 3: Supporting Supplements

Supplement	Why	Dose
Copper Low	Cofactor for lysyl oxidase (collagen cross-linking). Should be framed as zinc-induced copper depletion prevention; no evidence oral copper enhances wound healing beyond sufficiency. Note: oral copper at 1–2 mg does NOT create GHK-Cu complex.	1–2 mg/day
Betaine HCl REMOVE Very Low	VALIDATION WARNING: FDA banned from OTC in 1993. Only N=6 pilot study. Contraindicated with NSAIDs/corticosteroids used post-surgery. “Suboptimal stomach acid” claim unsupported; physiologically backwards for surgical stress. Should be removed from protocol.	650–2000 mg with meals
Glucosamine Chondroitin Very Low	Zero wound healing studies; oral delivery achieves <2% of GAG incorporation. VF researchers use injectable hydrogels, not oral supplementation. Chondroitin is a VF lamina propria component but oral route is unproven for delivery.	Gluc 1500 mg, Chon 1200 mg
Boron Low	Best wound healing evidence is for topical boron, not oral. Inflammatory biomarker data from N=8. EFSA classifies as non-essential. Supports Ca/Mg/vitamin D metabolism.	3–6 mg/day
Taurine Low-Medium	One perioperative meta-analysis (reduced infection OR 0.59); no human wound healing RCTs. Antioxidant, anti-inflammatory. Supports mitochondrial function during recovery.	500–2000 mg/day
MSM Very Low	EFSA rejected collagen formation claim. In vitro study showed MSM DELAYED wound healing at higher concentrations. Antiplatelet concerns (bleeding risk post-surgery).	1000–3000 mg/day
Gentian + Skullcap REMOVE / WARN Very Low	VALIDATION WARNING: Zero wound healing evidence. Skullcap has documented hepatotoxicity risk and adulteration concerns (germander). Gentian has MAO inhibition that interacts with perioperative drugs. Should be removed from protocol.	Per product label
Calcium D-Glucarate REMOVE / WARN Very Low	VALIDATION WARNING: Zero wound healing evidence. Modulates glucuronidation of post-surgical drugs (morphine, benzodiazepines, antibiotics) with no interaction studies. Could alter medication efficacy. Should be removed from protocol.	500–1500 mg/day
Broccoli Seed Extract Low-Medium	Sulforaphane: potent Nrf2 activator. Best of the Tier 3 supplements; strong mechanism, keloid fibroblast in vitro data. But no surgical recovery RCTs.	10–50 mg sulforaphane
Iodine WARN: HIGH DOSE Very Low	VALIDATION WARNING: “Antiseptic” claim is a topical-to-oral category error. 1000 mcg/day is near the upper limit with thyroid toxicity risk (Wolff-Chaikoff effect / thyrotoxicosis). No oral wound healing evidence. Only 150 mcg/day justified as deficiency prevention.	150 mcg/day only
Liver Detox Support Low	Phase I/II detox support. Claims about “clearing” medications faster are oversimplified.	Per product label

The Inflammation Paradox

Critical Timing

Do NOT aggressively suppress inflammation during days 1–5. Early inflammation is essential — it recruits immune cells, clears debris, and initiates healing. Save potent anti-inflammatories (curcumin, quercetin, high-dose omega-3s) for after day 3–5.

During days 1–5, focus on: hydration, vitamin C, zinc, probiotics, and prescribed pain management.

Part 3

Peptides for Recovery

Peptides are short amino acid chains that act as signaling molecules. Several have potent wound-healing and anti-scarring properties, though most lack FDA approval.

GHK-Cu The Gene Modulator Confidence: Low-Medium

Naturally occurring tripeptide-copper complex. Plasma levels decline from ~200 ng/mL at age 20 to ~80 ng/mL by age 60 (note: plasma decline numbers from unpublished 1973 thesis).

Gene modulation studies used MCF7 breast cancer and PC3 prostate cancer cell lines, not fibroblasts or wound tissue — relevance to wound healing uncertain
Directly inhibits the TGF-β1/Smad2/3 fibrotic pathway
The “70% collagen increase” figure is COL1 mRNA (not protein) from an LED combination study, not GHK-Cu alone
Stimulates collagen I, III, IV plus decorin and GAGs
Balances MMP/TIMP ratios for proper ECM remodeling
~~Healing time reductions of 30–50% documented~~ Correction: no peer-reviewed study documents this figure; it appears on commercial websites only

Dosage

Topical: 2–4% cream/serum, twice daily to wound/scar

Injectable: 1–2 mg subQ, 2–3x/week for 8–12 weeks

Safety: Excellent topical profile. Injectable on FDA high-risk compounding list. Not FDA-approved for injection.

TB-500 The Anti-Fibrotic Confidence: Low

Synthetic 7-amino acid heptapeptide (Ac-LKKTETQ) derived from thymosin beta-4. Correction: TB-500 is a 7-mer, NOT the 43-amino acid TB4 protein. Most cited evidence is for the full TB4 protein, not TB-500 specifically.

Prevents fibroblast-to-myofibroblast conversion — the central event in scar formation (TB4 evidence)
Reduces TGF-β1, TGF-βR II, Smad2, and Smad3 expression (TB4 evidence)
Produces organized, mature collagen fibers vs disorganized scar collagen (TB4 evidence)
Increased re-epithelialization by 42–61% over controls (TB4 evidence)

Dosage

Loading: 2–2.5 mg subQ every other day for 4–6 weeks

Maintenance: 1–2 mg, 1–2x/week. ~~Long half-life (7–10 days)~~ Correction: actual half-life is 0.5–2 hours (PK data). The 7–10 day figure originated from bodybuilding forums, not pharmacokinetic studies.

Safety: Limited human data. Cancer risk is significant: 4x tumor size and 4x metastatic nodules in mouse melanoma model. No human trials of TB-500 specifically (only TB4). Not FDA-approved. WADA-banned.

BPC-157 The Angiogenesis Promoter Confidence: Low

15-amino acid peptide from human gastric juice. Uniquely stable in stomach acid — can be taken orally.

Activates dual nitric oxide pathways (VEGFR2 & Src-caveolin-1-eNOS)
Enhances ERK1/2 signaling for cell proliferation
Upgrades the “collagen-inflammatory cells-angiogenesis” triad
Large preclinical evidence base, but 80%+ from single research group (Sikiric/Zagreb) with undisclosed conflicts of interest; zero published negative results (statistical red flag)
Promotes healing across tendon, ligament, muscle, bone, skin, and gut (animal data)

Dosage

Injectable: 250–500 mcg/day subQ (split AM/PM), near wound site

Oral: 100–500 mcg, 1–2x daily (better for gut healing)

Post-surgery: 300–400 mcg/day weeks 1–2, taper to 200 mcg/day by weeks 7–12

Safety: Only 26 total human subjects ever published. FDA Category 2 concern. One cancelled clinical trial without explanation. WADA-banned.

KPV Targeted Anti-Inflammatory Confidence: Very Low

Tripeptide from alpha-MSH. Anti-inflammatory without melanogenic effects. Zero human clinical trials for any indication.

Blocks NF-κB pathway, reducing TNF-α and IL-6
Antimicrobial against S. aureus. Correction: C. albicans claim used (CKPV)2 synthetic dimer, not native KPV tripeptide
Accelerates re-epithelialization (preclinical only)
Flexible: topical, oral, or injectable

Combination Protocols

“Wolverine Stack” (BPC-157 + TB-500)

Experimental & Cutting-Edge Approaches

Verteporfin — The YAP Inhibitor

The most promising anti-scarring intervention in development Medium-High (science) Very Low (clinical)
Verteporfin is an FDA-approved drug for macular degeneration that also potently inhibits YAP — the master switch turning regenerative fibroblasts into scar-forming fibroblasts.
    

The Stanford Breakthrough

2021 (Science): Mascharak & Longaker showed verteporfin injection at wounding prevents scarring and drives regeneration in mice.
Feb 2025 (Science Translational Medicine): Same results in red Duroc pigs — the most human-like scarring model. A single injection at wounding prevented scarring.
Phase 1/2 trial registered: NCT06944249 — testing verteporfin in human surgical wounds (melanoma excision sites). Not yet recruiting.
First human use: Dr. Barghouthi (Westminster Medical Group, London) in hair transplant surgery — reported 33% visual scar reduction and new hair growth at 4 months. Validation note: This is N=1 with subjective assessment only; no human efficacy data from controlled trials exists.

Mechanism

Verteporfin prevents YAP from entering the nucleus and activating Engrailed-1 transcription. This keeps fibroblasts regenerative (ENF) instead of converting to scar-forming (EPF). It breaks the positive feedback loop: tension → YAP → collagen → more tension → more YAP.

Practical Status

Not yet available for routine clinical use. Must be administered at wounding or very shortly after. Off-label use has begun in hair transplants. Watch this space closely.

Other Approaches (Ranked by Evidence)

Approach	Evidence	Mechanism	Notes
Botox	Strong	Reduces mechanical tension at wound sites	Multiple human studies favor scar reduction (exact “20/23” figure could not be verified from published reviews). Mostly Asian population facial wound data. Medium-High
Mechanical Offloading	Strong	Physically reduces wound tension	Embrace device. Clinical trials in high-tension areas.
Topical Losartan	Moderate	TGF-β modulation via AT1R blockade	Correction: animal scar data is for topical losartan, not oral as previously stated. Topical under investigation. Low-Medium
Pirfenidone Gel	Moderate	Inhibits TGF-β, reduces fibroblast proliferation	Efficacy in pediatric burn scar trials. Approved topically in Mexico only.
PRP	Moderate	Concentrated growth factors. Note: Piezo1-YAP/TAZ mechanism is from a hypothesis paper, not experimental validation.	Established clinical use, variable results.
Red Light Therapy	Preclinical+	Enhances mitochondrial function via cytochrome c	630–850nm. Non-invasive, usable throughout recovery. GRADE umbrella review: zero high-certainty outcomes; 57% low, 26% very low certainty. Low
Laser Treatments	Preclinical+	Controlled thermal remodeling	Fractional CO2, pulsed dye. For existing scars, not prevention.
Fat Grafting	Preclinical+	Adipose-derived stem cells	Volume restoration + stem cell delivery. Growing evidence.
Decorin	Early	Neutralizes TGF-β directly	Fusion proteins in development.
Piezo1 / FAK Inhibitors	Early	Block mechanotransduction cascade	GsMTx4 (Piezo1), PF-573228 (FAK). Preclinical.

Part 5

VFSRAC-Specific Recovery

What Is VFSRAC?

Vocal Fold Shortening and Retrodisplacement of the Anterior Commissure. Developed by Dr. Hyung-Tae Kim at Yeson Voice Center (Seoul), refined over 18+ years. A 2024 Laryngoscope study documented outcomes from 506 patients.

The Surgery

Endoscopic (through mouth, no external incisions) • ~1 hour • General anesthesia

Step 1 — Tissue Removal: Epithelium removed from anterior 1/3 to 1/2 of vocal folds. Submucosal tissue and mucus glands dissected. Creates raw surfaces that will fuse.

Step 2 — Suture Placement: Two permanent nylon sutures at different vertical depths. Creates a funnel-shaped anterior commissure (vs. flat web in standard Wendler) promoting smooth laminar airflow.

VFSRAC vs Standard Wendler

Feature	Standard Wendler	VFSRAC
Web shape	Flat anterior web	Funnel-shaped passage
Sutures	Absorbable (Vicryl)	Permanent nylon
Suture planes	Single plane	Multiple vertical depths
Airflow	Can be turbulent	Smooth, laminar
Voice quality	Some breathiness	More natural-sounding
Singing	May be impaired	Generally preserved

Type II VFSRAC Results (2024)

Pitch Outcomes (Mean)

134.5 Hz

Pre-op

→

196.7 Hz

3 Months

→

212.3 Hz

6 Months

→

207.5 Hz

1+ Year

Vocal Fold Anatomy: Why Scarring Here Is Different

Vocal folds must vibrate at 100–300 Hz during phonation. Even minor scarring directly degrades voice quality. The lamina propria is only ~3mm thick.

The Lamina Propria (Three Layers)

Superficial (Reinke’s Space) — MOST CRITICAL. Loosely organized collagen/elastin. High hyaluronic acid (~6.4 mcg/mg). Gelatinous, fluid-like vibration. Most vulnerable to scarring.

Intermediate — Primarily elastic fibers. Forms part of the vocal ligament.

Deep — Dense collagen bundles. Borders the thyroarytenoid muscle.

When Vocal Fold Scarring Occurs

Abnormal collagen increases (Type III → stiff Type I). Elastin and hyaluronic acid decrease. Normal layered architecture disrupted. Fibroblasts become myofibroblasts. Result: Disrupted mucosal wave, increased stiffness, hoarseness, breathiness, limited range, vocal fatigue.

Yeson Voice Center Protocol

Absolute Silence

Weeks 1–4

No talking, whispering, humming, coughing, laughing, singing, throat clearing. Communicate via writing/text only.

Relative Voice Rest

Weeks 4–8

Very limited, gentle voice use. No loud voice or whispering. Full unrestricted use at ~2 months.

Early Rehabilitation

Months 2–3

Voice exercises begin. Voice sounds hoarse/rough — this is normal.

Active Remodeling

Months 3–6

Tissue remodeling continues. Swelling resolves. Pitch gradually improves.

Adaptation

Months 6–12

Brain-muscle coordination retraining. Resonance work. Pitch stabilization.

Full Maturation

12+ Months

Final voice quality achieved.

Dietary Restrictions

Spicy foods, caffeine, and alcohol forbidden for 4 months. Water at 2 hours post-surgery. Soft foods at 4 hours.

Activity Restrictions

No sports for ~6 weeks. No straining or heavy lifting. No general anesthesia requiring intubation for at least 6 months (web dehiscence risk).

Anti-Reflux Protocol

Arguably the most important aspect of recovery

Laryngopharyngeal reflux (LPR) — stomach acid reaching the throat — can dissolve sutures, chemically burn healing tissue, and ruin outcomes. Many people have “silent reflux” without heartburn.

Medication

PPI (omeprazole/esomeprazole): 40 mg twice daily minimum
Duration: at least 1–3 months (some surgeons recommend longer)
Consider H2 blocker (famotidine) at bedtime for nighttime breakthrough

Behavioral

No eating within 3 hours of lying down
Sleep with head elevated 30° (wedge pillow)
Avoid triggers: spicy, citrus, tomatoes, onions, fizzy drinks, chocolate, fatty foods
No caffeine (increases acid AND relaxes lower esophageal sphincter)
No alcohol. Small, frequent meals.

Hydration & Humidification

Nebulized saline is superior to steam

Steam particles are too large to reach the vocal folds. Nebulized isotonic saline (0.9% NaCl, 3–4 micron particles) reaches and moisturizes them directly. Use an ultrasonic nebulizer 2–4 times daily. Steam still helps (increases blood flow). Combine both. Run a humidifier in the bedroom. Drink 2L+ water daily.

Substances & Behaviors to Avoid

Avoid	Why	Duration
Smoking/vaping	Epithelial damage, inflammation, impaired healing	Permanent
Alcohol	Bleeding, dehydration, reflux	4 months
Caffeine	Dehydrates VFs, promotes reflux	4 months
Spicy food	Reflux, mucosal irritation	4 months
Throat clearing	Slams folds together. Instead: sip water, swallow.	Always
Whispering	Creates MORE tension than soft normal speech	Always avoid
Catching colds	Coughing can disrupt sutures. Paranoid hand hygiene.	During recovery

Supplements Specifically Relevant to Vocal Folds

Quercetin VF-Specific Data Confidence: Low-Medium

Dose 500–1000 mg/day starting ~day 5 post-op

Has antifibrotic effects on vocal fold fibroblasts in one unreplicated animal study. Acts via TGF-β1/Smad signaling (not AKT/mTOR). Animal model: oral quercetin reduced VF scarring, lowered fibroblast density, improved collagen fiber organization. Validated: Tier 3 evidence. Only supporting human RCT was for cesarean section, not vocal folds. Promising but preliminary.

Supplement	VF-Specific Relevance
Vitamin C	Essential for collagen synthesis in VF repair
Zinc	Supports wound healing and cell division
Vitamin A	Critical for epithelial cell growth/differentiation. Supports re-epithelialization of deepithelialized VF surfaces.
Bromelain	Clinical evidence for reduced inflammation in vocal cord injuries
Omega-3s	Reduce VF swelling (stop 1–2 weeks pre-surgery)
Glucosamine/Chondroitin	Chondroitin sulfate is a component of VF lamina propria
Hyaluronic Acid	Critical VF component. Research focuses on injectable HA; oral bioavailability to VFs uncertain.

Voice Therapy (Essential, Not Optional)

Pre-Surgery Therapy

Understand your vocal mechanism
Develop good vocal habits
Set realistic expectations
Begin resonance work (surgery raises pitch; resonance determines perceived femininity)

Post-Surgery Therapy

Adapting to the physically altered instrument
Relaxing neck/shoulder muscles that unconsciously compress the voice
Breath support and posture
Resonance placement
Intonation and prosody patterns
Gradually building vocal stamina

Key insight: Finding the right speech therapist matters enormously. Prioritize practical, understandable instruction.

Community Tips from VFSRAC Patients

From detailed patient diaries, particularly from Susan’s Place:

Prepare communication strategies before surgery (printed cards, text apps)
Recovery is two distinct processes: physical healing (months) and mental retraining (months to years)
Learning feminine speech patterns is like “learning a new language”
Voice will sound worse before it gets better — this is completely normal
Phone calls with strangers are a useful progress benchmark
Plan voice therapy for at least 1 year post-surgery
Emphasize resonance work alongside pitch development
Expect fatigue when maintaining new patterns; consistency > perfection
No misgendering during voice rest is an unexpected early benefit

Part 6

Integrated Protocol Timeline

Pre-Surgery

2–4 Weeks Before

Start: Vitamin C, Zinc, D3+K2, Collagen peptides, S. boulardii, Arginine, Glutamine, NAC, Taurine. Bromelain 3 days before.

Stop 2 weeks before (bleeding risk): Curcumin, fish oil, vitamin E (high dose), garlic, ginkgo, ginseng.

Optional peptides: BPC-157 250–500 mcg/day (priming). Thymosin Alpha-1 1.6 mg 2x/week (immune).

Surgery Day & Days 1–5

Acute Phase

Focus: Let inflammation do its job. No anti-inflammatory supplements yet.

Continue: Vit C, Zinc, Collagen, S. boulardii, Glutamine, Arginine
All prescribed meds (cough suppressant, antibiotics, PPI, analgesics)
Absolute voice rest. Nebulize saline 2–4x/day. Humidifier. 2L+ water.
Head elevated 30°. No eating 3hrs before bed.
Peptides: BPC-157 300–400 mcg/day. TB-500 2–2.5 mg every other day.

Days 5–14

Transition to Anti-Fibrotic

Add back: Curcumin, Quercetin (VF anti-fibrotic!), Bromelain, Centella asiatica.

Peptides: Continue BPC-157. Continue TB-500. Begin GHK-Cu 1–2 mg 3x/week.

Weeks 2–6

Proliferative Phase

Add MSM, Boron, Glucosamine Chondroitin. Continue all above.

TB-500 transitions to maintenance (1–2 mg, 1–2x/week)
VFSRAC: Absolute silence weeks 1–4. Gentle voice use begins ~week 4.

Weeks 7–12

Remodeling Phase

Continue core supplements. BPC-157 tapers to 200 mcg/day. GHK-Cu topical continues. TB-500 reduces or discontinues.

VFSRAC: Voice therapy begins (~month 2). Gentle exercises, resonance work.

Months 3–12+

Long-term Remodeling & Adaptation

Continue Quercetin + Bromelain, Vit C, Zinc, D3/K2. PPI for 3+ months total. 30-day peptide washout at 12 weeks.

VFSRAC: Active voice therapy. Sports resume ~6 weeks. No intubation 6 months. Pitch stabilizes. Final voice quality at 12+ months.

Part 7

Safety & Warnings

Supplements to STOP Before Surgery

Supplement	Stop When	Why
Curcumin/Turmeric	2 weeks before	Platelet inhibition, bleeding risk
Fish Oil / Omega-3s	1–2 weeks before	Bleeding risk
Vitamin E (high dose)	2 weeks before	Anticoagulant effects
Garlic supplements	1 week before	Inhibits platelet aggregation
Ginkgo biloba	2 weeks before	Bleeding risk
Ginseng	1 week before	May affect clotting
Ginger (high dose)	1 week before	May affect clotting

Peptide Safety

Risk	Details
Cancer	BPC-157, TB-500, GHK-Cu promote angiogenesis — could theoretically promote tumor growth. Screen before starting.
No FDA approval	Except Thymosin Alpha-1 (30+ countries, not US). Others are off-label / “research chemicals.”
Purity	Non-pharmaceutical-grade peptides may contain impurities. Use reputable sources with certificates of analysis.
Limited data	Dosing extrapolated from animal studies. Long-term human safety unknown.
Interactions	Discuss ALL peptides with surgeon/anesthesiologist before surgery.

Peptide Contraindications

Peptide	Contraindications
GHK-Cu	Wilson’s disease, copper metabolism disorders, copper allergy, active cancer
TB-500	Active cancer, pregnancy, competitive athletes (WADA-banned)
BPC-157	Active cancer (theoretical), pregnancy, competitive athletes (WADA-banned)
KPV	Limited data; caution with autoimmune conditions
Thymosin α-1 Medium	Organ transplant (immunosuppression), autoimmune flares. Note: “improved survival” claim overstated; study measured immune cell counts, not survival endpoint.

Critical VFSRAC-Specific Warnings

NO INTUBATION for 6 months — inform ALL healthcare providers. Intubation can cause web dehiscence. Carry a medical alert (smaller 5.0–5.5 tubes if emergency intubation is needed).
Absolute voice rest means ABSOLUTE — no whispering, mouthing words, humming, laughing, sighing, grunting, moaning.
Anti-reflux is non-negotiable — acid on healing vocal folds is a chemical burn.
Do not catch colds — coughing can destroy healing. Paranoid hand hygiene, avoid sick contacts.

Sources & Further Reading

Key Papers

Mascharak et al. (2021). “Preventing Engrailed-1 activation yields wound regeneration without scarring.” Science. doi:10.1126/science.aba2374
Mascharak et al. (2025). “Inhibiting mechanotransduction prevents scarring.” Sci Transl Med. PMID:39970235
Kim HT et al. (2024). “Update of VFSRAC for Voice Feminization.” The Laryngoscope. PMID:39115180
Quercetin antifibrotic effects on VF fibroblasts. PMC9827314
HA hydrogels for VF wound healing. PMC3732321

Clinical Trials

NCT06944249: Verteporfin for skin scarring (Phase 1/2)

Community Resources

Susan’s Place: VFSRAC recovery thread — susans.org/index.php?topic=234768
r/transvoice (Reddit)